An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid

Pathogenic events in Alzheimer's disease (AD) involve an imbalance between the production and clearance of the neurotoxic beta-amyloid peptide (Abeta), especially the 42 amino acid peptide Abeta1-42. While much is known about the production of Abeta1-42, many questions remain about how the peptide is degraded. To investigate the degradation pattern, we developed a method based on immunoprecipitation combined with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry that determines the Abeta degradation fragment pattern in cerebrospinal fluid (CSF). We found in total 18 C-terminally and 2 N-terminally truncated Abeta peptides and preliminary data indicated that there were differences in the detected Abeta relative abundance pattern between AD and healthy controls. Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%.

[1]  Lennart Eriksson,et al.  Model validation by permutation tests: Applications to variable selection , 1996 .

[2]  Gerrit Schüürmann,et al.  Quantitative structure-activity relationships in environmental sciences, VII , 1997 .

[3]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[4]  D. Selkoe,et al.  Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids , 1992, Nature.

[5]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[6]  Alistair Burns,et al.  Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .

[7]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[8]  L. Forno,et al.  P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. , 1996, The American journal of pathology.

[9]  S. Sisodia.  Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Nitsch,et al.  Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology , 2004, Neurodegenerative Diseases.

[11]  D. Beher,et al.  Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .

[12]  Henrik Zetterberg,et al.  Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry , 2006 .

[13]  M. Ball,et al.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.

[14]  C. Vigo‐Pelfrey,et al.  Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid , 1993 .

[15]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[16]  S. Sahasrabudhe,et al.  Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. , 1992, The Journal of biological chemistry.

[17]  D. Selkoe,et al.  Kinetics of Amyloid β-Protein Degradation Determined by Novel Fluorescence- and Fluorescence Polarization-based Assays* , 2003, Journal of Biological Chemistry.

[18]  C. Eckman,et al.  Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention , 2005 .

[19]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein α‐secretases , 2003 .

[20]  Erik Johansson,et al.  QSAR Model Validation , 2000 .

[21]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[22]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[23]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[24]  H. Wiśniewski,et al.  The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid* , 1996, The Journal of Biological Chemistry.